<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04429334</url>
  </required_header>
  <id_info>
    <org_study_id>MOT-C-204</org_study_id>
    <nct_id>NCT04429334</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support and Features of Systemic Inflammation.</brief_title>
  <acronym>ESSENTIAL</acronym>
  <official_title>Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients With ventiLatory Support (ESSENTIAL) A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inotrem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inotrem</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, in which one dose of nangibotide will&#xD;
      be tested versus placebo.&#xD;
&#xD;
      All patients with a diagnosis of COVID-19, and a requirement for respiratory support will be&#xD;
      considered for study participation. The applicable local requirements for informed consent&#xD;
      will be followed. Where permissible, an emergency consent procedure will be followed for&#xD;
      patients unable to provide consent by themselves. All potential study patients will receive&#xD;
      standard of care treatment throughout the study. Patients will receive a continuous&#xD;
      intravenous (i.v.) infusion of nangibotide at 1.0 mg/kg/h or a matching placebo. Treatment&#xD;
      with study drug must be initiated as early as possible but no later than 48 hours after the&#xD;
      initiation of ventilatory support (Patients will be treated for 5 days or until discharge&#xD;
      from critical care, whichever is sooner). Follow-up visits will be performed on days 8 and&#xD;
      14. The end of study visit is at day 28. A further follow up visit will be undertaken on day&#xD;
      60.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1:</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of adverse events until day 28</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2:</measure>
    <time_frame>28 days</time_frame>
    <description>Clinical Status (7-point Ordinal Scale) assessed at Day 28</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3:</measure>
    <time_frame>28 days</time_frame>
    <description>All-Cause mortality at day 28</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">730</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>nangibotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nangibotide</intervention_name>
    <description>nangibotide 1.0 mg/kg/h</description>
    <arm_group_label>nangibotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provided informed consent (emergency consent according to local regulations where&#xD;
             approved)&#xD;
&#xD;
          2. Age 18 to 75 years (inclusive)&#xD;
&#xD;
          3. Admitted to an intensive care unit&#xD;
&#xD;
          4. Treatment with High Flow Nasal Oxygen, non-invasive ventilation or invasive mechanical&#xD;
             ventilation for acute respiratory failure caused by COVID-19 for less than 48 hours&#xD;
&#xD;
          5. A PaO2:FiO2 ratio of &lt;200mmHg (&lt;26.7kPa) with a FiO2 ≥0.6&#xD;
&#xD;
          6. Confirmed laboratory diagnosis of COVID-19 within 7 days of meeting screening criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known pregnancy (positive urine or serum pregnancy test)&#xD;
&#xD;
          2. Currently receiving an immunomodulatory agent for the treatment of COVID-19 (including&#xD;
             participation in clinical trials of such agents where treatment allocation is blinded&#xD;
             or allocated on an open label basis).&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 40 kg/m2or weight ≥ 130 kg&#xD;
&#xD;
          4. Anticipated transfer to another hospital, which is not a study site within 72 hours&#xD;
&#xD;
          5. Expected to die within 6 months of treatment due to underlying chronic disease&#xD;
&#xD;
          6. Limitations of care in place during current hospital admission&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Jacques Garaud, MD</last_name>
    <role>Study Chair</role>
    <affiliation>INOTREM SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Jacques Garaud, MD</last_name>
    <phone>+33 (0)9 66 81 79 00</phone>
    <email>covtrem@inotrem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique universitaire Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-François Laterre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Fivez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Asfar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaëtan Plantefeve, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Germont et Gauthier</name>
      <address>
        <city>Bethune</city>
        <zip>62400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Vinsonneau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon - Bourgogne - Hôpital François Mitterrand</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre Quenot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Site la Roche sur Yon, les Oudairies</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85 925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Claude Lzcherade, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier le Manas</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Guitton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno François, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Melun</name>
      <address>
        <city>Melun</city>
        <zip>77000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mehran Monchi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samir Jaber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Réanimation Médicale, Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien Gibot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Dieu - CHU Nanates</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémie Lemarié, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul Mira, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil - Nouvel Hôpital civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ferhat Mezziani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle Mercier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Franch-Comté Site Trevenans</name>
      <address>
        <city>Trevenans</city>
        <zip>90400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julio Badie, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nangibotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

